PRNewsWire
03 Aug 2026, 08:43 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo study failed to achieve its primary endpoint in a statistically significant manner. — Failure of a Phase III clinical trial is a material blow to a biotech company's pipeline and potential future revenue streams.
-0.80Regeneron is facing a securities class action lawsuit alleging it made false and misleading statements regarding the success of the Fianlimab-Libtayo study. — Legal action for securities fraud creates financial liability and introduces regulatory risk and reputational damage.
-0.40Which stocks this story touches
The company is being sued for securities law violations in a class action lawsuit.
Continue reading
6 related stories
Search tags
The company is being sued for securities law violations in a class action lawsuit.
The company is facing a class action lawsuit alleging false and misleading statements regarding a failed clinical study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
